📊 RGNX Key Takeaways
Is RGNX a Good Investment? Thesis Analysis
RGNX is a biotech company with structurally unsustainable economics: $170M in revenue generates -$194M net losses and -$124M in operating cash burn annually, leaving only 3-4 months of cash runway at current burn rates. Flat YoY revenue growth combined with deepening losses and negative free cash flow of -$126M indicates the company is not advancing toward profitability and faces severe liquidity risk without immediate capital raises or dramatic operational improvements.
Why Buy RGNX? Key Strengths
- No long-term debt (Debt/Equity: 0.00x) reduces financial distress risk
- Current liquidity ratio of 2.38x provides near-term operational flexibility
- EPS deterioration slowed YoY (+18.1%), suggesting modest operational improvements
RGNX Investment Risks to Consider
- Critical cash burn of -$124M annually against only -$34.5M cash reserves (~3 month runway)
- Flat revenue growth (-0% YoY) while losses persist indicates no commercial traction or market acceptance
- Operating margin of -94.6% and net margin of -113.8% show severe operational unprofitability unsustainable long-term
- Negative free cash flow of -$126.4M and ROE of -188.7% demonstrate value destruction
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate sustainability
- Revenue growth acceleration and path to gross profitability
- Cash balance depletion rate and need for capital raise timing
RGNX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
RGNX Profitability Ratios
RGNX vs Healthcare Sector
How REGENXBIO Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RGNX Overvalued or Undervalued?
Based on fundamental analysis, REGENXBIO Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RGNX Balance Sheet & Liquidity
RGNX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: REGENXBIO Inc.'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-4.59 indicates the company is currently unprofitable.
RGNX Growth Metrics (YoY)
RGNX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $24.2M | -$59.6M | $-1.17 |
| Q2 2025 | $21.4M | -$53.0M | $-1.05 |
| Q1 2025 | $15.6M | $6.1M | $0.12 |
| Q3 2024 | $24.2M | -$59.6M | $-1.17 |
| Q2 2024 | $20.0M | -$53.0M | $-1.05 |
| Q1 2024 | $15.6M | -$63.3M | $-1.38 |
| Q3 2023 | $26.5M | -$61.9M | $-1.41 |
| Q2 2023 | $20.0M | -$68.2M | $-1.58 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RGNX Capital Allocation
RGNX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for REGENXBIO Inc. (CIK: 0001590877)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGNX
What is the AI rating for RGNX?
REGENXBIO Inc. (RGNX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGNX's key strengths?
Claude: No long-term debt (Debt/Equity: 0.00x) reduces financial distress risk. Current liquidity ratio of 2.38x provides near-term operational flexibility.
What are the risks of investing in RGNX?
Claude: Critical cash burn of -$124M annually against only -$34.5M cash reserves (~3 month runway). Flat revenue growth (-0% YoY) while losses persist indicates no commercial traction or market acceptance.
What is RGNX's revenue and growth?
REGENXBIO Inc. reported revenue of $170.4M.
Does RGNX pay dividends?
REGENXBIO Inc. does not currently pay dividends.
Where can I find RGNX SEC filings?
Official SEC filings for REGENXBIO Inc. (CIK: 0001590877) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGNX's EPS?
REGENXBIO Inc. has a diluted EPS of $-3.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGNX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, REGENXBIO Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RGNX stock overvalued or undervalued?
Valuation metrics for RGNX: ROE of -188.7% (sector avg: 15%), net margin of -113.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGNX stock in 2026?
Our dual AI analysis gives REGENXBIO Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGNX's free cash flow?
REGENXBIO Inc.'s operating cash flow is $-124.0M, with capital expenditures of $2.4M. FCF margin is -74.1%.
How does RGNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -113.8% (avg: 12%), ROE -188.7% (avg: 15%), current ratio 2.38 (avg: 2).